GENESIS Pharma
Sofia Egglezou has a diverse work experience in the pharmaceutical industry. Sofia began their career as a Research Assistant at the Thrombosis Research Institute in London in 1999. Sofia then moved on to work at Servier, where they started as a Sales Representative in 2000 and later became a Product Manager from 2001 to 2005. In 2005, they joined Genesis Pharma as a Product Manager and was promoted to Senior Product Manager in 2008. Sofia then took on various marketing roles within the company, including Marketing, Franchise Manager for Multiple Myeloma Disease and Marketing Manager for Haematology/Oncology. Most recently, Sofia has been serving as the Core Marketing Team Director at Genesis Pharma, where they provide strategic and operational support to all markets in the international region.
Sofia Egglezou holds a Master of Business Administration (M.B.A.) degree in Business Administration and Management from Athens University of Economics and Business (2010-2012). Sofia also holds a Master's Degree in Biochemistry from Imperial College London (1999-2000) and a BSc in Physiology & Biochemistry from the University of Reading (1995-1998).
This person is not in any offices
GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative pharmaceutical products for severe and rare diseases in Central and Eastern Europe. Founded in 1997 in Greece, GENESIS Pharma S.A. was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. In 1999, business activities were expanded in Cyprus through the creation of GENESIS Pharma (Cyprus) Ltd, and later on, in markets of Southeast Europe. GENESIS Pharma (Cyprus) Ltd, an affiliate (sister) company, now operates in Central and Eastern Europe, through its subsidiaries in Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia, Slovenia (EU) as well as North Macedonia and Serbia (Non-EU). GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with leading international pharma companies committed to cutting-edge R&D as well as biopharma companies with disruptive innovations for the development of targeted, specialized treatments for orphan diseases. For more information, please visit www.genesispharmagroup.com and www.genesispharma.com